Evidence-based recommendations for the use of WBC-reduced cellular blood components
dc.contributor.author | Ratko, Thomas A. | en_US |
dc.contributor.author | Cummings, Joseph P. | en_US |
dc.contributor.author | Oberman, Harold A. | en_US |
dc.contributor.author | Crookston, Kendall P. | en_US |
dc.contributor.author | DeChristopher, Phillip J. | en_US |
dc.contributor.author | Eastlund, D. Ted | en_US |
dc.contributor.author | Godwin, John E. | en_US |
dc.contributor.author | Sacher, Ronald A. | en_US |
dc.contributor.author | Yawn, David H. | en_US |
dc.contributor.author | Matuszewski, Karl A. | en_US |
dc.date.accessioned | 2010-06-01T19:44:52Z | |
dc.date.available | 2010-06-01T19:44:52Z | |
dc.date.issued | 2001-10 | en_US |
dc.identifier.citation | Ratko, Thomas A . ; Cummings, Joseph P . ; Oberman, Harold A . ; Crookston, Kendall P . ; DeChristopher, Phillip J . ; Eastlund, D. Ted; Godwin, John E . ; Sacher, Ronald A . ; Yawn, David H . ; Matuszewski, Karl A . (2001). "Evidence-based recommendations for the use of WBC-reduced cellular blood components." Transfusion 41(10): 1310-1319. <http://hdl.handle.net/2027.42/72881> | en_US |
dc.identifier.issn | 0041-1132 | en_US |
dc.identifier.issn | 1537-2995 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72881 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11606834&dopt=citation | en_US |
dc.format.extent | 95828 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 2001 American Association of Blood Banks | en_US |
dc.subject.other | DHHS = Department of Health and Human Services | en_US |
dc.subject.other | FNHTR(S) = Febrile Nonhemolytic Transfusion Reaction(S) | en_US |
dc.subject.other | HHV-8 = Human Herpesvirus 8 | en_US |
dc.subject.other | LOS = Length of Stay | en_US |
dc.subject.other | PC(S) = Platelet Concentrate(S) | en_US |
dc.subject.other | TRALI = Transfusion-related Acute Lung Injury | en_US |
dc.subject.other | UHC = University HealthSystem Consortium | en_US |
dc.subject.other | ULR = Universal Leukoreduction | en_US |
dc.subject.other | VATS = Viral Activation Transfusion Study | en_US |
dc.subject.other | VCJD = Variant CJD | en_US |
dc.title | Evidence-based recommendations for the use of WBC-reduced cellular blood components | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | From the Technology Assessment Group, Clinical Practice Advancement Center, University HealthSystem Consortium, Oak Brook, Illinois; the Department of Pathology, University of Michigan, Ann Arbor, Michigan; the Department of Transfusion Medicine and Coagulation, University of New Mexico Health Science Center, Albuquerque, New Mexico; the Blood Bank and Transfusion Medicine, University of Illinois at Chicago Medical Center; and the Hematology Clinical Laboratories, Loyola University Medical Center, Chicago, Illinois; the Division of Transfusion Medicine, Fairview-University Medical Center, Minneapolis, MN; Hoxworth Blood Center, University of Cincinnati Medical Center, Cincinnati, Ohio; and the Department of Pathology, Baylor College of Medicine, Dallas, Texas. | en_US |
dc.identifier.pmid | 11606834 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72881/1/j.1537-2995.2001.41101310.x.pdf | |
dc.identifier.doi | 10.1046/j.1537-2995.2001.41101310.x | en_US |
dc.identifier.source | Transfusion | en_US |
dc.identifier.citedreference | Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts blood transfusion. N Engl J Med 1999; 340: 438 47. | en_US |
dc.identifier.citedreference | Hogman CF. Improved utilization of blood due to systematic fractionation. Qual Assur Health Care 1990; 2: 207 12. | en_US |
dc.identifier.citedreference | Carter TH. Biotechnology, economics, and the business of blood. Biotechnology 1991; 19: 3 30. | en_US |
dc.identifier.citedreference | Lawrence VA, Birch S, Gafni A. The impact of new clinical guidelines on the North American blood economy. Transfus Med Rev 1994; 8: 232 41. | en_US |
dc.identifier.citedreference | Lane TA. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs. Arch Pathol Lab Med 1994; 118: 392 404. | en_US |
dc.identifier.citedreference | Heaton WA, Rebulla P, Pappalettera M, Dzik WH. A comparative analysis of different methods for routine blood component preparation. Transfus Med Rev 1997; 11: 116 29. | en_US |
dc.identifier.citedreference | Miller JP, Mintz PD. The use of leukocyte-reduced blood components. Hematol Oncol Clin North Am 1995; 9: 69 90. | en_US |
dc.identifier.citedreference | Dzik S, AuBuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000; 14: 34 52. | en_US |
dc.identifier.citedreference | Heddle NM, Blajchman MA. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995; 85: 603 6. | en_US |
dc.identifier.citedreference | Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36: 175 86. | en_US |
dc.identifier.citedreference | Heiss MM. Risk of allogeneic transfusions. Br J Anaesth 1998; 81: 16 9. | en_US |
dc.identifier.citedreference | Marquet RL, Busch OR, Jeekel J, et al. Are allogeneic blood transfusions acceptable in elective surgery in colorectal carcinoma? Eur J Cancer 1998; 35: 352 60. | en_US |
dc.identifier.citedreference | Vamvakas EC. Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives. J Clin Apheresis 1999; 14: 135 43. | en_US |
dc.identifier.citedreference | Thurer RL, Luban NLC, AuBuchon JP, et al. Universal WBC reduction (letter). Transfusion 2000; 6: 751 2. | en_US |
dc.identifier.citedreference | Busch M, Chamberland M, Epstein J, et al. Oversight and monitoring of blood safety in the United States. Vox Sang 1999; 77: 67 76. | en_US |
dc.identifier.citedreference | Goldbloom R, Battista RN. The periodic health examination: 1. Introduction. CMAJ 1988; 138: 617 8. | en_US |
dc.identifier.citedreference | 17. Guide to clinical preventive services an assessment of the effectiveness of 169 interventions. U.S. Preventive Services Task Force. Baltimore: Williams & Wilkins, 1989: xxvii xxxviii. | en_US |
dc.identifier.citedreference | Cook DJ, Guyatt GH, Laupacis A, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102 (4 Suppl): 305S 11S. | en_US |
dc.identifier.citedreference | Ferguson JH. The NIH Consensus Development Program. The evolution of guidelines. Int J Technol Assess Health Care 1996; 12: 460 74. | en_US |
dc.identifier.citedreference | Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970 1062. | en_US |
dc.identifier.citedreference | Schiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983; 62: 815 20. | en_US |
dc.identifier.citedreference | Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988; 72: 964 9. | en_US |
dc.identifier.citedreference | Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988; 71: 1402 7. | en_US |
dc.identifier.citedreference | Oksanen K, Kekom ki R, Ruutu T, et al. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components a randomized trial. Transfusion 1991; 31: 588 94. | en_US |
dc.identifier.citedreference | Van Marwijk Kooy M, van Prooijen HC, Moes M, et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmu-nization: a prospective, randomized trial. Blood 1991; 77: 201 5. | en_US |
dc.identifier.citedreference | Williamson LM, Wimperis JZ, Williamson P, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization a prospective, randomized study. Alloimmunisation Study Group. Blood 1994; 83: 3028 35. | en_US |
dc.identifier.citedreference | Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85: 824 8. | en_US |
dc.identifier.citedreference | 28. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861 9. | en_US |
dc.identifier.citedreference | Verdonck LF, de Graan-Hentzen YC, Dekker AW, et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 1987; 2: 73 8. | en_US |
dc.identifier.citedreference | De Graan-Hentzen YCE, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989; 29: 757 60. | en_US |
dc.identifier.citedreference | Gilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. The Neonatal Cytomegalovirus Infection Study GroupM. Lancet 1989; 1: 1228 31. | en_US |
dc.identifier.citedreference | De Witte T, Schattenberg A, Van Dijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990; 50: 964 8. | en_US |
dc.identifier.citedreference | Bowden RA, Slichter SJ, Sayers M, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplantation. Blood 1991; 78: 246 50. | en_US |
dc.identifier.citedreference | Eisenfeld L, Silver H, McLaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992; 32: 205 9. | en_US |
dc.identifier.citedreference | Van Prooijen HC, Visser JJ, van Oostendorp WR, et al. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994; 87: 144 7. | en_US |
dc.identifier.citedreference | Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598 603. | en_US |
dc.identifier.citedreference | Narvios AB, Przepiorka D, Tarrand J, et al. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant 1998; 22: 575 7. | en_US |
dc.identifier.citedreference | Preiksaitis JK. The cytomegalovirus- safe blood product: is leuko reduction equivalent to antibody screening? Transfus Med Rev 2000; 14: 112 36. | en_US |
dc.identifier.citedreference | Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001; 285: 1592 601. | en_US |
dc.identifier.citedreference | Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513 6. | en_US |
dc.identifier.citedreference | Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344: 573 8. | en_US |
dc.identifier.citedreference | Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841 5. | en_US |
dc.identifier.citedreference | Tartter PI, Mohandas K, Azar P, et al. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998; 176: 462 6. | en_US |
dc.identifier.citedreference | Van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97: 562 8. | en_US |
dc.identifier.citedreference | Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97: 1180 95. | en_US |
dc.identifier.citedreference | Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001; 41: 691 712. | en_US |
dc.identifier.citedreference | Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315 21. | en_US |
dc.identifier.citedreference | Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999; 6: 420 6. | en_US |
dc.identifier.citedreference | Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331: 625 8. | en_US |
dc.identifier.citedreference | Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999; 39: 231 8. | en_US |
dc.identifier.citedreference | Ness PM. Transfusion medicine: an overview and update. Clin Chem 2000; 46: 1270 6. | en_US |
dc.identifier.citedreference | Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284: 229 35. | en_US |
dc.identifier.citedreference | Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685 90. | en_US |
dc.identifier.citedreference | Holland PV. Viral infections and the blood supply (editorial). N Engl J Med 1996; 334: 1734 5. | en_US |
dc.identifier.citedreference | Kruskall MS. The perils of platelet transfusions (editorial). N Engl J Med 1997; 337: 1914 5. | en_US |
dc.identifier.citedreference | Klein HG. Will blood transfusion ever be safe enough? (editorial). JAMA 2000; 284: 238 40. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.